However, the FGFR4 inhibitor BGJ398 showed synergy with IGF-1R inhibitor AEW54 in an ARMS cell line, suggesting that FGFR4 may be a promising target in treatment resistance prevention (Wachtel et al., 2014). This evidence concerns the gene IGF1R and alveolar rhabdomyosarcoma.